These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31468315)

  • 21. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
    Kerwin EM; Spangenthal S; Kollar C; St Rose E; Reisner C
    Respir Res; 2018 Mar; 19(1):38. PubMed ID: 29506504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.
    Ferguson GT; Reisner C; Pearle J; DePetrillo P; Maes A; Martin UJ
    Pulm Pharmacol Ther; 2018 Apr; 49():67-74. PubMed ID: 29567116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology.
    D'Urzo AD; Cazzola M; Hanania NA; Buhl R; Maleki-Yazdi MR
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2805-2819. PubMed ID: 30233171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
    Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
    Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology.
    Taylor G; Warren S; Dwivedi S; Sommerville M; Mello L; Orevillo C; Maes A; Martin UJ; Usmani OS
    Eur J Pharm Sci; 2018 Jan; 111():450-457. PubMed ID: 29055732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycopyrrolate and formoterol fumarate for the treatment of COPD.
    Grillet PE; Le Souder C; Rohou J; Cazorla O; Charriot J; Bourdin A
    Expert Rev Respir Med; 2021 Jan; 15(1):13-25. PubMed ID: 32772582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Budesonide/Glycopyrrolate/Formoterol Fumarate Co-suspension Metered Dose Inhaler: A Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease.
    Nigro SC; Sobieraj DM
    Ann Pharmacother; 2022 May; 56(5):582-591. PubMed ID: 34382422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
    Martinez FJ; Rabe KF; Ferguson GT; Wedzicha JA; Singh D; Wang C; Rossman K; St Rose E; Trivedi R; Ballal S; Darken P; Aurivillius M; Reisner C; Dorinsky P
    Am J Respir Crit Care Med; 2021 Mar; 203(5):553-564. PubMed ID: 33252985
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
    Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD.
    De Backer W; De Backer J; Vos W; Verlinden I; Van Holsbeke C; Clukers J; Hajian B; Siddiqui S; Jenkins M; Reisner C; Martin UJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2673-2684. PubMed ID: 30214185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
    Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
    Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
    Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.
    Dhungana S; Criner GJ
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2307-2312. PubMed ID: 28814858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects.
    Reisner C; Miller J; DePetrillo P; Maes A; Siddiqui S; Martin UJ
    Pulm Pharmacol Ther; 2018 Dec; 53():33-38. PubMed ID: 30218695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
    Riario-Sforza GG; Ridolo E; Riario-Sforza E; Incorvaia C
    Expert Rev Respir Med; 2015 Feb; 9(1):23-33. PubMed ID: 25547422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials.
    Zheng J; Xu JF; Jenkins M; Assam PN; Wang L; Lipworth BJ
    Respir Res; 2020 Mar; 21(1):69. PubMed ID: 32164675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease.
    Carter NJ
    Drugs; 2013 May; 73(7):741-53. PubMed ID: 23677802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Inhaled Glycopyrronium Bromide in COPD: A Randomized, Parallel Group, Dose-Ranging Study (GLIMMER).
    Kerwin E; Feldman G; Pearle J; De La Cruz L; Edwards M; Beaudot C; Georges G
    COPD; 2021 Apr; 18(2):181-190. PubMed ID: 33709856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.